Loma Linda University

TheScholarsRepository@LLU: Digital Archive of Research,
Scholarship & Creative Works
Update

Loma Linda University Publications

9-2000

Update - September 2000
Loma Linda University Center for Christian Bioethics

Follow this and additional works at: http://scholarsrepository.llu.edu/update
Part of the Bioethics and Medical Ethics Commons
Recommended Citation
Loma Linda University Center for Christian Bioethics, "Update - September 2000" (2000). Update.
http://scholarsrepository.llu.edu/update/64

This Newsletter is brought to you for free and open access by the Loma Linda University Publications at TheScholarsRepository@LLU: Digital Archive
of Research, Scholarship & Creative Works. It has been accepted for inclusion in Update by an authorized administrator of
TheScholarsRepository@LLU: Digital Archive of Research, Scholarship & Creative Works. For more information, please contact
scholarsrepository@llu.edu.

LOMA LINDA UNIVERSITY CENTER FOR CHRISTIAN BIOETHICS

Volume 16, Number 2 (September 2000)

TAKANOBU KINJO, SCOTT
WINTERS AND NICOLE
WURSCHER GRADUATE
WITH DEGREES IN ETHICS
AND MINISTRY

Takanobu Kinjo of Okinawa, Japan,
pd Nicole Elizabeth Wurscher from the
"tate of Washington received their MA
degrees in biomedical and clinical ethics
from Lorna Linda University in August
of this year. Scott Keith Winters, from
Lincoln, Nebraska, received an MA
degree in clinical ministry the same
month. He was the first student to
receive this degree from LLU.
Mr. Kinjo, Mr. Winters, and Ms.
Wurscher are three of the 1,192 undergraduate and graduate students to graduate from Lorna Linda University in
2000. The others are receiving degrees
and certificates in the allied health professions, dentistry, medicine, nursing,
public health, and the natural and
behavioral sciences.
The graduations of Mr. Kinjo and
~1s. Wurscher bring the number of those
who have completed the MA degree in
ethics at LLU to seventeen. Eighteen
graduate students are now working
toward this degree. Thirteen are working toward the MA degree in clinical
ministry.
Mr. Kinjo, who graduated from La
Sierra University in 1996 with an undergraduate degree in psychology, anticipates returning to Japan for a while
before continuing his education either

L

in the United States or in the United
Kingdom. Ms. Wurscher, who graduated
with a bachelors degree in biology from
Walla Walla College in 1998, plans to
continue her career and education in this
country. Mr. Winters, who received his
BA degree in 1993 from Union College
in Nebraska, plans to finish his Clinical
Pastoral Education at Sutter Medical
Center in Sacramento.
Mr. Kinjo wrote a thesis analyzing
recent controversies in Japan regarding
whole brain death criteria and organ
transplantation. For her final project, Ms.
Wurscher designed a web site for dental
ethics and prepared two papers. One of
these reviews recent debates in the
United States about "medical futility"
and the other discusses ways to make
advance medical directives more effective. Mr. Winters did a final project on
spirituality and values clarification ...
DOCTOR ORR'S RELIGION: GOOD,
NOT-SO-GOOD, AND VERY GOOD!

Note: David R. Larson made the following remarks at an August farewell gathering in honor of Dr. and Mrs. Robert Orr
at Lama Linda University Medical Center.
For me, as for all of you, it has been
a great pleasure to work with Dr.
Robert Orr at Lorna Linda University
for the past ten years. It seems like
only yesterday that I was in St. Louis
for meetings of the Society for
Bioethics Consultation. While there I
had an opportunity to ask Dr. Mark
Continued on page 7

ROBERT AND JOYCE ORR
RETURN TO VERMONT

Dr. and Mrs. Robert D. Orr have
returned to Vermont, the state they
call "home." It is also where all three
of their adult children now reside. Dr.
Orr, who has served as the director of
clinical ethics at Lorna Linda
U niversity ~1edical Center since 1990,
has accepted a similar position at the
University of Vermont.
Dr. Orr received his undergraduate education at Houghton College in
New York. He studied medicine at
McGill University in Canada. After
serving as a physician in the Navy, he
practiced family medicine for a
number of years in Vermont where he
was named "family physician" for the
entire state.
After their years of service in
Vermont, the Orrs moved to the
Midwestern portion of the United
States where Dr. Orr studied clinical
Continued on page 8
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Commentary

Medical Theodicy Today
by Richard Rice
The wonderful title of a new book
aptly expresses the goal of its contents.
Pain Seeking Understanding, edited by
Margaret E. Mohrmann and Mark J.
Hanson (Cleveland: Pilgrim Press,
1999) is neither a book on theodicy per
se, nor a how-to book for sufferers or
caregivers. Instead, it probes an area
between these concerns-the relation
between theological convictions and
the practical demands of medical care.
It is therefore an example of "medical
theodicy," or, as ,David Larson nicely
puts it, "theodicy with a clinical edge."
This book contains essays by
twelve different scholars, including
physicians, theologians, philosophers,
and ethicists. Part 1, "Clinical
Perspectives," looks at the ways specific individuals come to terms with suffering. The authors argue that sufferers
seek a meaning that is practical rather
than theoretical, partial rather than
comprehensive. A medical theodicy,
then, is "practical, experiential, and
paradoxical." Rather than reconciling
abstract propositions about God, it
seeks to make things of form and beauty out of lived anxiety and pain.
Part 2, "Theological Views," pre-

sents some contrasting theologicalphilosophical approaches to suffering.
Does traditional theodicy have practical value? Daniel P. Sulmasy says yes,
and construes suffering as an
inescapable experience of human finitude. Wendy Farley says no. "Suffering
does not require explanation so much
as redemption." Accordingly, compassion is theodicy's ultimate work. We
should be present to one another in our
suffering just as God is radically present to us. Elliot N. Dorff discusses the
Jewish emphasis on the body as integral to the person and the important
practice of visiting the sick. Per
Anderson, drawing on Reinhold
Niebuhr's so-called "serenity prayer,"
argues that we can help people accept
and find meaning in things that cannot
be changed, contra the attitude that
pervasive technology engenders.
Part 3 examines several diverse
issues-the "secular problem of evil"
the fact that all of us, religious or not,
face the twin obligations of relieving
the suffering of others and fulfilling our
own potential as persons; the response
of Christian faith to genetic testing,
with its fatalistic overtones; and the
need for bioethics to turn from medicine's traditional attempt to eliminate
suffering and take up the challenge of
finding meaning in suffering.
This is a valuable collection of
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essays, primarily because it emphasizes
the problem of suffering. Over the
years philosophers and theologians
have devoted their attention largely
the problem of evil as a logical conun
drum, while health-care givers have
devoted their attention to the problem
of pain, and relief of physical discomfort. Both concerns broach, but do not
directly address, the experience of
suffering as a threat to personal
meaning, and that is precisely the
concern of this book. Among its central
features are the following. First, it
acknowledges the complexity of the
problem. Suffering is inevitable and
inexplicable. It admits of no easy
solutions. Second, in calling for a
practical theodicy, and doing theodicy,
the collection values theodicy-the
traditional attempt to locate suffering
within a framework of cosmic
meaning. Although the collection
challenges traditional theodicy in
various ways, it does not reject the
enterprise out of hand. If suffering is
more than pain, a distinction made
more than once in this collection, then
theodicy's attempt to find meaning ir
suffering, itself "represent[s] a kind (
relief from suffering." Third, it draws
on the reflections of various thinkers,
religious and non-religious, clinicians
as well as philosophers and theologians. Fourth, the discussion substantiates the "postmodern" insight that
meaning lies in the realm of the
individual and the particular, rather
than the general, and finds natural
expression in narrative rather than
discursive forms of speech.
Although the book has many of
the virtues of a symposium, it also has
some of its characteristic shortcomings. The general theme is practical
theodicy, but it is not clear that this is
the concern of all the essays. The last
three pieces in particular seem to go
in different directions. In addition,
the different essays place varying
demands on the reader. Some are
highly readable, while others contain
tightly constructed arguments.
In all, the book is an important
contribution to the ongoing quest f,
greater under~tanding of and morL.~
effective ways to respond to suffering.
I'm glad I read it, I recommend it, and
I'll use it in my classes ...
Update Volume 16, Number 2

Changing our Genes:
Medical Promises and Ethical Threats
by Anthony J. Zuccarelli, PhD
During the last two decades genetics has emerged from
the research laboratory to become a powerful biomedical
technology. Public awareness of the uses and potential misuses of genes and genetic information has grown as a result of a
rapid-fire series of high-impact applications-DNA fingerprinting, presymptomatic genetic testing, genetically modified food plants, animal cloning, human embryonic stem cell
lines, transgenic animals, the Human Genome Project and
human gene therapy. The pace and sophistication of these
advances has led some to predict that the next 50 years will
witness an explosion of genetic applications rivaling those
from physics, chemistry and the material sciences in the
previous half-century. Gene therapy, as one of these
interconnected developments, promises enormous benefits
for treating human disease. But what hazards and ethical
dilemmas follow in its train?
Gene therapy is the introduction of genetic material into
human patients in order to alter the expression of particular
genes. The goal of these alterations is to treat, cure, or ultimately prevent a disease or disability. Gene therapy should
not be confused with cloning, which has overwhelmed the
ublic media in recent years. Human cloning would result in
l1e birth of an individual with essentially the same genetic
makeup as an existing person. It is distinctly different from
gene therapy, both scientifically and ethically.
In this discussion I will describe some basic features and
define two major classes of gene therapy. After reviewing
methods that may be used to introduce new genes into
humans, we will examine a few concrete examples, and finally focus on the ethical concerns raised by the prospect of
putting new genes into people.
At the start, let's examine several features of gene therapy. In view of the rapid pace of developments, I have projected current capabilities into the near future. There is little
question that these improvements will occur, only when and
how they will occur.
1. The introduced genetic material may be DNA, RNA,
or a modified form of these molecules. (Elsewhere I may use
"genes" or simply "DNA" to refer to all of these substances.)
Recall that DNA is the permanent storage medium for genetic information in cells. RNA is a versatile molecule, performing a variety of cellular tasks, but its best-known function is to
carry selected bits of genetic information from the DNA in
the nucleus to the protein factories that reside in the cell body
(cytoplasm).
2. The introduced genetic material may come from
almost any source- humans, animals, plants, microbes, virus;-or it may be entirely synthetic with no counterpart in
nature. Later examples illustrate a few of these possibilities.
3. In current trials the added genetic material is usually
supplemental, an addition to the patient's genome that corresponds to defective or poorly expressed genes already preUpdate Volume 16, Number 2

sent. However, considerable effort is directed at developing
"gene targeting" in which the introduced material will precisely replace the defective gene.
4. Strictly speaking, the introduced genetic material is
not itself therapeutic. In most cases it influences the amounts
of various proteins that cells make. The proteins are the
molecular machines that accomplish the desired change.
5. The new genetic material may have an intentionally
temporary effect or it may be permanent. A genetic treatment
for an acute condition, infectious disease, or cancer, for example, might be deliberately short-term. On the other hand, a
patient with an inherited or chronic disease may need lifelong therapy. Eventually we can expect genetic therapies to
be configured to respond dynamically to the patient's condition so that they are expressed when needed.
There are two broad categories of gene therapy, distinguished by the particular tissues that are modified. Somatic
gene therapy targets the body cells of the patient, any organ
or tissue other than the reproductive cells. Tissues in many
different organs have been proposed for somatic gene therapy-bone marrow, liver, muscle, skin, thyroid, intestinal
epithelium, lungs, blood vessels, heart, brain, etc. Somatic
therapy has the same intent as conventional medicine-to
relieve the suffering or save the life of the patient under treatment. There is no attempt to produce an effect that extends
beyond the individual patient. In fact, heritable effects are
specifically and conscientiously avoided.
The methods of somatic gene therapy are experimental,
but the pace of investigation is rapid and vigorous. By the end
of 1999, about 400 gene therapy trials involving over 3,200
patients had been approved in the United States.
Nevertheless, substantial improvements must be achieved
before any particular application can be used outside a clinical study.
Germline gene therapy, on the other hand, would
make genetic changes that extend to the reproductive or
germ cells that develop into eggs or sperm. Such alterations
could be transmitted to the offspring of the original patient.
In fact, that is an intentional goal of germline therapy. It seeks
to achieve a fundamentally new objective for a medical treatment, the heritable correction of the genome.
Germline therapy offers a significant advantage over
somatic gene therapy in that it eradicates the genetic cause of
a disease condition and prevents it from being propagated to
offspring. Some argue that only germline treatments produce
real cures, rather than the palliative or symptomatic treatment of individuals.' A consequence of such therapy is that
the health care system is relieved of treating successive genAnthony J. Zuccarelli, PhD
professor, microbiology/molecular genetics
School of Medicine
Loma Linda University
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potentially initiate cancer.
erations of affected individuals from the same family.
Non-viral vectors. There are several alternatives to
Germline therapy has not yet been attempted in humans
using
viruses. Liposomes, lipid-DNA complexes and bare
and, indeed, no one knows how to accomplish it efficiently or
DNA
have some promising applications. So far, these ha~
safely. Experience with germline modifications of laboratory
proven
much less efficient in most situations. It is possib ,
and domesticated animals suggests that it may be some time
that
a
better
understanding of how viruses enter cells may be
before such alterations can be attempted in humans.
useful
in
designing
artificial agents that mimic their efficienNevertheless, the NIH and the FDA have begun preliminary
cy
and
specificity,
but
avoid their deficiencies.
study of a proposal to treat a fetus in utero,2and a March 1998
In
vivo
and
ex
vivo
methods. The gene delivery probsymposium at UCLA brought together the thought-leaders
lem
has
had
an
impact
on
how gene therapy is performed. In
of genetic medicine to consider the feasibility and advantages
of germline therapy.3
vivo gene therapy, where the
genetic material is introduced
Somatic gene therapy, for its part,
"The
challenge
has
been
to
put
directly into the patient, has been
has come under intense scrutiny since
very
disappointing. Not enough of
September 1999, after the death of 18these genes into the cells where
the
patient's
cells are effectively
year-old Jesse Gelsinger, a participant
they
would
be
most
useful."
treated.
Consequently,
most early
in a clinical trial at the University of
4
ex vivotrials
were
performed
Pennsylvania. The deaths of several
outside
the
patient.
In
this
approach,
cells
from
a
target
tissue
participants in other trials, attributed to their underlying disare
obtained
from
the
patient.
Genetic
material
is
introduced
ease, have also come to light. These incidents emphasize the
into these cells as they grow in culture using any of the means
need for more animal testing, better risk assessment,
described
earlier. Successfully modified cells are selected and
improvements in informing participants of risks, full reportexpanded
by further growth in culture. Finally they are
ing of adverse events, and ways to minimize the influence of
returned
to
the patient so that they can colonize a target tiscommercial interests on the trials. Most commentators presue.
Direct
in
vivo treatment is the long-term goal because of
dict, however, that these cases will not stop further experiits
simplicity
and economy. E x vivo treatments represent a
mentation, but intensify the search for improved methods.
transitional
expedient
that will be used until the efficiency of
How might therapeutic DNA be introduced into
vectors
improves
enough
for in vivo use. Germline modificapatients? For more than 20 years we have been able to isolate
be performed in the undefined
tions,
for
comparison,
would
genes that could provide clinical benefits-clotting factor
realm
between
in
vivo
and
ex
vivo-genes
must be physicallv
genes for hemophiliacs, growth factor genes to accelerate
introduced
into
a
zygote
(pre-embryo)
or
into the four-t
wound healing, insulin genes for type I diabetics, tumor supeight cell embryo in the laboratory.
pressor and cytokine genes for cancer treatment, and genes
The wide range of potential applications for gene therafor arterial growth to help patients with coronary disease. The
py is best illustrated by describing a few examples of attemptchallenge has been to put these genes into the cells where
ed or proposed uses.
they would be most useful. The "delivery problem" -getting genes into cells-is a major technical roadblock to sucRetroviral therapy for adenosine deaminase deficess. At present there are two basic approaches.
ciency. The first authorized attempt at gene therapy was to
treat a rare genetic defect, deficiency of the enzyme adenoViral vectors. Virus-mediated gene transfer involves
sine deaminase. Absence of this enzyme causes accumulation
packaging therapeutic genes into engineered virus particles
of a substance that poisons essential cells of the immune systhat can carry them into patient cells. These vectors exploit
tem. The resulting severe combined immune deficiency synthe incredibly efficient mechanisms that viruses use to introdrome (SCIDS) leaves the sufferer exquisitely susceptible to
duce their own genes into cells during infection. Three difinfections by even the mildest pathogens. SCIDS patients
ferent virus groups have been used widely-Ientiviruses and
usually do not survive early childhood. (You may remember
other retroviruses (relatives of HIV), adenoviruses (common
photos of David who lived to age 12 inside a sterile plastic
cause of "colds" and conjunctivitis) and adeno-associated
bubble.) In 1990 Michael Blaese and French Anderson convirus (unrelated to adenoviruses and not known to cause
structed a modified retrovirus to carry a functional copy of the
human disease). Other virus groups are also under considerahuman adenosine deaminase gene. They used the virus to
tion. Typically, the virus is disabled by removing all or part of
introduce the gene into bone marrow cells extracted from a 4its genome so that it cannot kill or proliferate in the cells it
year-old SCIDS sufferer, Ashanti DeSilva, then returned the
enters, unless that is a desired result. One or more therapeutreated cells to the patient. Presence of the genetically moditic genes replaces the viral material.
fied cells contributed to measurable improvements in her
All existing viral vectors suffer from practical limitations.
immune system. Ten years after her initial treatment, Ashanti
The tendency of adenoviruses to provoke severe immune
now attends school and participates in the activities of a typiresponses in sensitized patients was the likely cause of Jesse
Gelsinger's death. Furthermore, genes carried by adenovirus
cal 14-year-old with no more than an occasional cold. But
genetic therapists cannot claim a cure. The treated blood cel'
vectors usually have only a temporary effect because this
act for only a few months, so the process must be repeate
virus enters cells that have a short life in the body. Vectors
periodically. Furthermore, Ashanti continues to receive oral
based on the small adeno-associated virus offer very limited
supplements of the missing enzyme. s In 1999, two ninespace for therapeutic genes, but they may provide a more susmonth-old boys with SCIDS were given new genes in
tained effect. Lentiviruses and other retroviruses may disrupt
France. They now have immune cells that were missing
normal genes in the patient genome and such changes could
4
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before treatment and the constant infections that they suffered since birth have disappeared.
Drug activation gene to kill cancer. Gancyclovir, an
r nntiviral drug, kills cells infected with herpes virus because
. i_he virus makes an enzyme, called thymidine kinase, that
converts gancyclovir into a cellular poison. One gene therapy
experiment used this reaction to kill glioblastoma brain
tumors. The thymidine kinase gene was put into a retrovirus
vector that was injected into the tumor. Because these
retroviruses could infect only dividing cells, they attacked
proliferating tumor cells rather than normal, quiescent brain
cells. Later, the patient was given gancyclovir, which
specifically killed the tumor cells with viral thymidine kinase.
The treatment was even more effective than expected due to
the so-called "by-stander effect" in which gancyclovir kills
both sensitized cancer cells as well as their nearest neighbors.
The method is now being tested on several other cancer
types.
,
DNA immunization. Naked DNA coding for proteins
that appear on the surface of a pathogen can function like a
vaccine. Unexpectedly, when DNA is injected directly into
muscle some of it enters cells surrounding the injection site.
If the DNA is properly designed, these cells will express the
genes for a time, secreting the corresponding proteins and
displaying them on their surfaces. Since the new proteins are
from a pathogen and are not normally found in the body, they
are identified as "foreign" by the immune system and targeted by antibodies and phagocytic cells. The immunological
. "memory" of this event can protect the person from infection
, ) y a real pathogen that displays the same proteins.
;
p53 skin cancer cream. There are about 100,000 new
cases of squamous cell skin cancer in the United States each
year, most due to excessive exposure to sunlight. After a sunburn, skin "peels" because a gene called p53 triggers the
death of cells that have suffered severe UV damage.
Programed cell death is a desirable protective response to
DNA damage. However, if the p53 gene were itself inactivated in some earlier event (like a childhood sunburn), its
protective function would be lost. Cells with p53 defects
have taken the first steps on the pathway to cancer because
they survive subsequent genetic damage. One proposed
genetic therapy is a skin cream that contains copies of the p53
gene in liposomes. Applied to the skin, the supplementary
p53 gene would cause the immediate self-destruction of precancerous cells. The treatment would be used on individuals
at risk for skin cancer or with history of pre-cancerous lesions.
Viral mediated gene therapy for cystic fibrosis. The
most serious manifestation of cystic fibrosis is the susceptibility of sufferers to frequent lung infections. These cause
inflammation, destruction of lung tissue, respiratory failure,
and premature death. The underlying defect is in the CFTR
gene that is normally responsible for regulating the flow of
ions across cell membranes. The gene was isolated in 1992
and has been engineered into a recombinant adeno-associat-ed virus. The original virus genome was eliminated to make
/oom for the CFTR gene. Applying the virus to airway
epithelial cells in the form of an inhalant can reverse the deficiency and avoid the most severe consequences of the disease.
Ethical considerations. Laudably, the Human
Update Volume 16, Number 2

Genome Program was the first national science initiative to
specifically designate a portion of its budget for systematic
examination of the ethical, legal and social implications of
genetic technology. One consequence of the resulting discussions is the general acceptance of the proposition that the
introduction of therapeutic genes into somatic cells is conceptually similar to the transplantation of cells or organs, or
the implantation of artificial medical devices. It raises the
same ethical and social issues as those widely used medical
procedures.
1. "Do no harm" is the first principle of medicine. A
treatment must offer a measurable prospect of benefit, and
that benefit must outweigh the possibility of adverse events.
The requirement for a favorable risk/benefit analysis is formally embedded in the clinical testing program of the United
States. Somatic therapies will emerge from clinical trials
when there is good evidence that they offer solid benefits and
avoid significant harm.
On the flip side, since somatic genetic therapies may
always impose some inherent risk, they should probably not
be used to alter conditions that are not life-threatening nor
severely disabling. In spite of public demand and possible
financial inducements, using genes to engineer cosmetic
enhancements-like reversing pattern baldness or changing
superficial appearance-should not be considered until the
attendant risk approaches zero. I would hope that genetic
medicine could avoid the excesses of cosmetic surgery.
The risk/benefit calculus becomes more complex in
germline gene therapy because we cannot foresee all the consequences of permanent human genetic modifications. We
know too little about the multiple roles of individual genes,
and the proteins they make, in highly interactive living systems. Some consequences may not become apparent for
years or even generations. Will the eradication of a genetic
feature deemed undesirable because of its primary effect also
eliminate some secondary, but highly valued, trait?
This concern, however, may be addressed by recent proposals that would permit patients, under medical supervision,
to reverse gene additions non-invasively. There are several
molecular systems that could accomplish the feat of
precisely excising an artificially introduced DNA segment
and sealing up the gap. An oral drug, similar to an antibiotic
or hormone, could trigger the enzymatic reversal. Like the
"uninstall" option on your computer, individuals would be
able to undo genomic changes made by their progenitors, or
exchange them for more recent versions. 6
2. Christian healing commission. A second principle is
the Christian obligation to alleviate suffering and preserve
life. The Scriptures portray God as endlessly concerned with
the moral and physical restoration of his creatures. "And he
sent them to preach the kingdom of God, and to heal the
sick" (Luke 9:2). Christ gave explicit instructions to continue
his healing ministry. To the extent that it can prevent disease
and restore health, we are obliged to investigate the potential
of genetic therapies. Christian health professionals have a
moral obligation to use the most effective methods to prevent
or treat disease.
3. Imago Dei. The doctrine of the image of God in
humanity is a fundamental Christian belief. Though there
may be disagreements among Christians as to what consti-

5

organ transplantation, advanced forms of assisted reproductutes God's image, we generally hold that the distinctive traits
tion, and various surgical techniques. This is a health policy
that set us apart from other earthlife include abstract reasonissue that must be addressed adequately before we can claim
ing, appreciation of spiritual values, and the ability to make
to be a fair and just society.
decisions based upon moral principles. We should avoid any
6. God endowed human beings with intelligence an"
genetic alteration that might interfere with these capacities.7
creativity, and charged us with responsibility for the planet.
Some claim that genetic technology offends or violates
He intends for us to grow in our understanding of the princithe "natural order." Respect for God and created life,
ples of life, including the function of our bodies. Ethical
however, does not preclude human intervention in nature.
research and examination can only increase our appreciation
Humankind has regularly abandoned the course of nature.
of God's wisdom and goodness.
Our world includes heart disease, diabetes, cancer and AIDS.
As no other creatures on earth, we persist in probing and
Few would argue that these particular manifestations of
questioning, attempting to understand
nature are good or that we should allow
nature and make it accountable. Within
them to progress unopposed. From the
"Respect for God and created the medical realm, we are powerfully
Christian perspective, nature is not
God, that it should be worshiped. On
life, does not preclude human driven to control disease--conditions
that disrupt the order and harmony that
the contrary, we are assigned the task of
intervention in nature."
God intended. We are invited to use
preserving the good in nature and
the
knowledge he gives us.
restoring humanity to a condition in
Consequently, gene therapy need not be an expression of
which it can appre~iate the character and goodness of God.
human pride or arrogance. As long as the aim is to alleviate
4. Human autonomy. God places enormous value on
suffering, and we use our creativity with purpose, courage,
human freedom. For this reason genetic alterations that
caution, contingency and compassion, keeping in mind the
would limit an individual's abilities, restrict participation in
protection of the defenseless and helpless, genetic medicine
society, reduce autonomy, or undermine personal freedom
has the same moral justification as traditional medicine. On
must be rejected. Autonomy may be violated if germline
the other hand, an attempt to redesign ourselves into creatherapy is attempted without a means for reversal. This printures with new and superlative powers would be perilous. A
ciple also supports the development of genetic therapies as a
balanced view of our God-likeness should remind us that we
means to satisfy the needs of prospective parents, at risk for
tamper with fundamental human attributes at great risk.
transmitting serious genetic diseases, to bear healthy chilMany caution that the use of gene therapy will put us on
dren. Pressure to use germline gene therapy, for example,
a slippery slope with no dividing line between therapy an
"will not likely come from government or dictators with a
enhancement. In rebuttal, we do not prohibit every
desire to make a super race, but rather from parents who
endeavor that, if pursued without restraint, might lead to
desire to improve the chances of their biological children." 6
undesirable consequences. Everything we do carries risks
The principle of autonomy requires informed consent.
which we attempt to balance against the benefits of meaPatients must be able to weigh the potential risks and advansured action. That is the domain of ethics. Our deliberation
tages and freely select a course of action without coercion or
implies that we can prescribe limits for our behavior. The
duress. The ability to give informed consent may itself be
reflection of God's image that remains invites us to
undermined if genetic therapists are unable to predict with
responsible action. •
confidence the long-range effects of a genetic change.
Consequently, reliable means for reversing an alteration will
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afford it, will the distribution of desirable traits become badly
Line?" Journal of Medicine and Philosophy 14(6):681-93,
skewed among different groups in society? These questions
December, 1989.
point out a general flaw in our health-care system since they
apply with equal force to other advanced medical services6
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Siegler of the University of Chicago if
he thought Dr. Orr might serve Lorna
r "\ inda well as a clinical ethicist. Dr.
Jiegler's face beamed with joy as he
assured me that we could make no better choice. He was right!
F or the past decade, we at Lorna
Linda have enjoyed a wonderfully collaborative relationship between those
of us who are primarily teachers and
those of us who are primarily clinicians,
something that is not always the case in
the world of bioethics. The Clinical
Ethics Service, the Center for Christian
Bioethics and the Master of Arts program in biomedical and clinical ethics
all testify to the success of this relationship. Dr. Orr's presence, personality
and professionalism have done more
than we can tell to make all this possible.
We are going to miss Bob. We are
also going to miss Joyce, his splendid
partner.
Nevertheless, even on solemn
occasions like this one, honesty is
required. This means we must concede
.t"hat in some respects our relationship
) ith Dr. Orr has been awkward. This is
especially true with respect to his religious orientation, something about
which there is good news, not-so-good
news and very good news.
The good news is that, like many
of us, Dr. Orr received his basic religious education from people who are
theological descendants of the eighteenth century English reformers, John
and Charles Wesley. Before studying
medicine at McGill University, he
attended a small liberal arts college in
New York that is operated by those
who descend theologically from these
two brothers.
Although many don't know it, and
some apparently don't care, Seventhday Adventists are also part of the
Wesleyan stream of Christian thought
and life. Ellen White and other theological "grandchildren" of the Wesley
brothers founded
Lorna Linda
University and many other medical and
educational institutions around the
"torld. Because we share this common
!~ligious heritage, it has been easy to
be comfortable when working with
Bob.
The not-so-good news is that Dr.
Orr is not always as faithful to his
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Wesleyan heritage as we would prefer.
He has been known to fraternize with
those who are Christians of different
sorts: to speak well of them, to work
with them and even to worship with
them!
Given his religious background,
we expected that when he and Joyce
moved to Southern California they
would join a congregation belonging to
anyone of the several Wesleyan
denominations in our area. But they
didn't! Each week they worship with
another group of Christians whose
name I shall not mention in this company. For many of us, this has been a
source of intense perplexity and pain
for ten long and difficult years!
The very good news is that Dr.
Orr's Wesleyan background surfaces in
unmistakable ways even when none
expect this to happen. This is a comforting verification of the words of
Scripture, "train up a child in the way
he should go, and when he is old, he
shall not depart from it."
Nowhere is this more evident than
with respect to the question of human
freedom. Strange though it may seem,
Dr. Orr now associates with some
Christians who actually believe in predestination! Nevertheless, sometimes
when we are least expecting it, the
emphasis of his Wesleyan religious
background on human freedom, and
the uncertainty about the future it necessarily implies, erupts from him in
surprising but telling ways.
I shall mention only one actual
example, a report Dr. Orr gave us himself with his usual professional seriousness and self-criticism at one of our
weekly
Clinical
Ethics
Case
Conferences.
Dr. Orr revealed that since we last
met he had been requested to visit an
elderly woman in our medical center
who was conscious though very near
death. After discussing all the options
as best they could, even though a respirator was assisting her breathing, this
patient, her gathered relatives and Dr.
Orr all agreed that it would be best no
longer to fight her approaching demise
but to accept its inevitability with calm
Christian dignity.
Dr. Orr, as he always does in difficult cases like this one, explained to
the patient what would happen. "We
will give you some medicine that will

enable to you to fall into a deep and
comfortable sleep," he said. "While
you are sleeping, we will gradually turn
down the respirator. Without even
knowing it, you will then stop breathing. You will experience no grief, stress
or discomfort as you peacefully slip
away."
At this poignant moment, one of
the patient's loved ones exclaimed,
"And the next thing you know, you will
be with Jesus!"
Dr. Orr quickly replied, "And
maybe not!" He actually did!
Dr. Orr thinks he knows why he
startled everyone-the elderly patient,
her relatives and even himself-by
saying this. As he explained at our
Clinical Ethics Case Conference with
obvious embarrassment, he believes he
was trying to make clear that not every
patient who is extubated immediately
expires. Some continue breathing on
their own for a while longer, a few for
many more years.
But I know the real reason why Dr.
Orr said, "And maybe not!" In his
heart of hearts, despite his more recent
religious wanderings, he is still a
Wesleyan! As such, he senses, even if
he is not always consciously aware of it,
that because of human freedom the
future is somewhat uncertain for all of
us!
Thank you Bob for ten wonderful
years! Jerry Winslow left Lorna Linda
for four years and then returned. I
hope that someday you will come
"home" too!
Note: After these comments, Dr. Orr
said he would return to Loma Linda if
"this is predestined!" ..
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medical center's administration.
In addition to his work on campus, Dr. Orr has been an active leader
in the California Medical Association,
the Christian Medical and Dental
Society and the American Society of
Bioethics and the Humanities.
Dr. Orr successfully led a transition from a "committee approach" to a
"consultant approach" in clinical
ethics at Lorna Linda University
Medical Center. In the vast majority of
cases,
the
Institutional
Ethics
Committee at LL UMC no longer conferred about difficult ethical issues

The Orrs
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ethics with Dr. Mark Siegler and others at the University of Chicago. After
completing this program, they moved
to Redlands, California and Dr. Orr
joined the faculty at Lorna Linda.
At first Dr. Orr divided his time
between family medicine and clinical
ethics. Although he retained his appointment in family medicine, as the years
went by and the demands for his consulting services increased, he invested
increasing amounts of his time in the
area of clinical ethics. His work as a clinical ethicist has been financed by the

pertammg to patient care. Instead,
health care professionals, as well as
patients and their families, called for
professional counsel from Dr. Orr a
the clinical colleagues he mentoreL..
Once each week, the entire team of
ethicists at Lorna Linda, both clinical
and theological, met to discuss cases in
which Dr. Orr and his associates
recently served as consultants. For a
decade, this arrangement has successfully blended the greater efficiency of
the "consultant approach" with the
advantages of collaboration in the
"committee approach.".
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